All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-04-27T09:04:27.000Z

Is vedolizumab effective for preventing lower GI acute GvHD?

By Alice Hyde, Mark Maitland, Jennifer Higgins
Featured
Yi-Bin Chen
Apr 27, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lower GI acute GvHD.

Bookmark this article

During the 2023 Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, the GvHD Hub was pleased to speak to Yi-Bin Chen, Massachusetts General Hospital, Boston, US. We asked, Is vedolizumab effective for preventing lower gastrointestinal (GI) acute graft-versus-host disease (aGvHD)?

Is vedolizumab effective for preventing lower GI acute GvHD?

Chen begins by summarizing the justifications, methods, and data from the phase III randomized, double blind, placebo-controlled GRAPHITE trial of vedolizumab. GRAPHITE was a prospective large cohort trial with a primary endpoint of lower GI aGvHD-free survival by Day 180. Chen explains the trials clinical significance, highlighting overall survival, relapse free survival, and safety.

Chen concludes by discussing the impact of current clinical trials on future treatment and prevention strategies for GvHD, as well as the impact of new interventions on patient populations.

More about...
Acute graft-versus-host diseaseGRAPHITETCT 2023Vedolizumab

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox